D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

D. E. Shaw & Co. Inc. lowered its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 83.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,043 shares of the company's stock after selling 143,203 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.05% of Stoke Therapeutics worth $309,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. increased its stake in Stoke Therapeutics by 29.2% in the fourth quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock valued at $220,000 after purchasing an additional 4,512 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Stoke Therapeutics during the 4th quarter valued at approximately $1,423,000. Bank of New York Mellon Corp grew its stake in Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,330 shares in the last quarter. Rhumbline Advisers grew its stake in Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after purchasing an additional 2,787 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in Stoke Therapeutics during the 4th quarter valued at approximately $113,000.

Insider Activity

In related news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. The trade was a 5.72% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

STOK has been the topic of a number of research analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Finally, HC Wainwright lowered their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $23.20.

Stoke Therapeutics Stock Performance

Shares of STOK stock traded up $0.30 on Thursday, reaching $9.73. 453,308 shares of the company's stock traded hands, compared to its average volume of 709,422. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $17.58. The company has a market capitalization of $531.23 million, a P/E ratio of -4.63 and a beta of 1.20. The business's 50 day moving average price is $8.32 and its two-hundred day moving average price is $9.78.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Research analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.